Transforming biological data into clinical benefits

Transcription

1 Transforming biological data into clinical benefits Through: Development of new diagnostics Precession Medicine Pathway Analysis for better drug design

2 Unique Bio Marker Discovery Tool (ANNs) granted US Patent, pending Europe An advanced bioinformatics tool. Can cope with noise, complexity and non-linearity found in biological data Comprehensive and robust data-mining. Will search through 50 million model combinations for an optimum solution Every model developed is optimised for performance on an unseen data set. Models predict well for new blind cases. Provide decision tools that are applicable to all cases that could present Finds the most optimal solution. E.g. 6 genes compared with 78 genes (comparison with other, recursive methods) Unique Innovative approach to Meta Data Analysis for identification of Key markers and Pathway Analysis

3 Advantages of ANN technology Non- linear solutions are not constrained by linear search parameters Adaptive not constrained by hypothesis Generalised work well for new cases Identify biologically relevant targets Competitor Technologies do not use or are not suited to the identification of panels of markers, often linear attempt to analyse all of the markers on the array are time consuming and inefficient

4 Distribution of performance of single genes distilling out the most significant

5 This free to attend event was held as part of the SoLSTICE programme - a project part-funded by the European Regional Development Fund. Company Offering within the Field of Infectious Diseases An Insilico service and expertise that offers: Early/ Better Diagnosis of Disease Patient Stratification for better and more cost effective treatment Identification of Disease Pathway to assist Drug Design At much reduced cost.

6 This free to attend event was held as part of the SoLSTICE programme - a project part-funded by the European Regional Development Fund. Areas of Activity within the Infectious Diseases Arena M tuberculosis (Human TB Mycobacterium) - focus of work being done by our Chinese company Sepsis Major projects identifying diagnostic markers pre and post symptomatic. markers for Sepsis v SIRS, pulmonary and abdominal sepsis Bovine TB- Innovate Funded Project partners include Sapient Sensor and Public Heath England markers for field point of use test. Looking for partners with relevant sensor technology. Antibiotic Resistant drug need access to appropriate data sets, particular those that would complement work being done in Human TB.

7 Case History M tuberculosis A publically available dataset was used to identify a whole blood transcript signature that discriminates cases with latent TB from those with active. CompanDX s Biomarker Distiller was used to derive an optimal gene transcript signature discriminating between latent TB and active TB in a UK cohort(n=300) Using our technology we were able use the expression how these genes changed when transiting from the latent to active form of the disease. Clinical Validation and product development now being undertaken by our Chinese subsidiary

8 This free to attend event was held as part of the SoLSTICE programme - a project part-funded by the European Regional Development Fund. M tuberculosis Biomarkers of TB Latent vs. Active Marker 3 Gene Panel discriminating between Latent and Active TB at; 99% sensitivity and 74% specificity Genes are up-regulated in transiting between Latent and active TB Train Test Evaluation Error Error Error Kinase LACTB DUSP

9 Seeking 1. Partners that can provide or help us obtain suitable Data Sets to run through our technology 2. Diagnostic companies seeking Biological Markers for their Platforms 3. Companies that wish to help develop and Licence our IP 4. Companies and Organisations that require a High Level Data Mining or an Insilco Service

10 For more information contact; Professor Graham Ball (Director of Informatics) or Gwent Paylor (Business Development)